reported that 39% of patients in the GLB group received therapeutic-dose anticoagulation, compared with 27% in the non-bleeding group; although this difference did not reach statistical significance -likely due to the limited sample size-anticoagulant therapy may still increase the risk of GLB [ 31 ].
← all excerpts
Clinical features, treatments and prognosis of COVID-19 (Omicron) and hemorrhagic colitis: a case series study.
1
—
—